Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Kerr

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
Nature Clinical Practice. Oncology|October 22, 2008
Capecitabine: have we got the dose right?Rachel Midgley, David J Kerr
The New England Journal of Medicine|September 8, 2010
Can we treat cancer for a dollar a day? Guidelines for low-income countriesDavid J Kerr, Rachel Midgley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?David J Kerr, Rachel Midgley
Nature Clinical Practice. Oncology|August 4, 2005
Adjuvant chemotherapy for stage II colorectal cancer: the time is right!Rachel Midgley, David J Kerr
Nature Reviews. Clinical Oncology|June 12, 2013
Biological markers: Tailoring treatment and trials to prognosisDavid J Kerr, Yuankai Shi
The New England Journal of Medicine|September 11, 2009
British lessons on health care reformDavid J Kerr, Mairi Scott
Ebiomedicine|September 26, 2021
Personalising cancer medicine with prognostic markersDavid J Kerr, Li Yang
Expert Opinion on Drug Metabolism & Toxicology|June 13, 2015
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developmentsDavid J Bell, David J Kerr
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thoughtRachel S Midgley, David J Kerr
Journal of Epidemiology and Global Health|March 14, 2019
Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for HealthLyndsay S Baines, David J Kerr
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
Nature Clinical Practice. Oncology|October 22, 2008
Capecitabine: have we got the dose right?Rachel Midgley, David J Kerr
The New England Journal of Medicine|September 8, 2010
Can we treat cancer for a dollar a day? Guidelines for low-income countriesDavid J Kerr, Rachel Midgley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker?David J Kerr, Rachel Midgley
Nature Clinical Practice. Oncology|August 4, 2005
Adjuvant chemotherapy for stage II colorectal cancer: the time is right!Rachel Midgley, David J Kerr
Nature Reviews. Clinical Oncology|June 12, 2013
Biological markers: Tailoring treatment and trials to prognosisDavid J Kerr, Yuankai Shi
The New England Journal of Medicine|September 11, 2009
British lessons on health care reformDavid J Kerr, Mairi Scott
Ebiomedicine|September 26, 2021
Personalising cancer medicine with prognostic markersDavid J Kerr, Li Yang
Expert Opinion on Drug Metabolism & Toxicology|June 13, 2015
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developmentsDavid J Bell, David J Kerr
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2013
Adjuvant chemotherapy for stage II colon cancer: less complicated than we thoughtRachel S Midgley, David J Kerr
Journal of Epidemiology and Global Health|March 14, 2019
Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for HealthLyndsay S Baines, David J Kerr
Pageof 12